8月6日，PDS Biotechnology Corporation（PDSB）通过美国证券交易委员会（SEC）文件披露，公司已正式批准一项人员精简方案。此举旨在调整运营成本结构，使其与既定战略优先事项保持一致。这家生物技术企业正通过削减人力开支，来应对当前阶段的资金配置需求。
8月6日，PDS Biotechnology Corporation（PDSB）通过美国证券交易委员会（SEC）文件披露，公司已正式批准一项人员精简方案。此举旨在调整运营成本结构，使其与既定战略优先事项保持一致。这家生物技术企业正通过削减人力开支，来应对当前阶段的资金配置需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.